On August 31, HBM HOLDINGS-B fell 5.24% in regular trading to HK$14.16, with turnover of HK$18.99 million, extending the prior session's decline as the market continued to digest disappointing interim results.
The company reported H1 revenue of US$122 million, up 20.9% year-over-year, but net profit fell 11.16% to US$64.85 million. The profit erosion was primarily driven by a 64.6% surge in R&D costs to US$29.6 million and a 126.3% jump in administrative expenses to US$16.67 million, largely attributable to rising headcount costs and litigation-related fees. While molecular licensing and collaboration revenue grew to US$113 million, the sharp expense expansion compressed margins, prompting sustained negative market reaction to the revenue-profit divergence.
Separately, on August 27 the company announced a board reshuffle, with executive director Rong Yiping departing for personal reasons and Chen Youchen and Liu Yi appointed as new executive directors.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments